Cardio Diagnostics Launches PrecisionCHD Test in India

Reuters

Jan 07

<a href="https://laohu8.com/S/CDIO">Cardio Diagnostics</a> Launches PrecisionCHD Test in India

Cardio Diagnostics Holdings Inc., a leader in precision cardiovascular medicine, has announced its first international expansion through a strategic partnership with Aimil Ltd. and Dr. Lal PathLabs Limited to launch the PrecisionCHD™ test in India. This collaboration introduces Cardio Diagnostics' advanced epigenetics and AI-driven technology for the detection and management of coronary heart disease to the Indian market. The move aims to improve early detection and personalized treatment of heart disease across Dr. Lal PathLabs’ extensive healthcare network, reflecting Cardio Diagnostics’ commitment to advancing precision medicine globally.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardio Diagnostics Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260107882108) on January 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2601087223"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601087223\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601087223?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 19:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601087223","market":"fut","top_or_hot":-1,"title":"Cardio Diagnostics Launches PrecisionCHD Test in India","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CDIO\">Cardio Diagnostics</a> Launches PrecisionCHD Test in India\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CDIOW\">Cardio Diagnostics</a> Holdings Inc., a leader in precision cardiovascular medicine, has announced its first international expansion through a strategic partnership with Aimil Ltd. and Dr. Lal PathLabs Limited to launch the PrecisionCHD™ test in India. This collaboration introduces Cardio Diagnostics' advanced epigenetics and AI-driven technology for the detection and management of coronary heart disease to the Indian market. The move aims to improve early detection and personalized treatment of heart disease across Dr. Lal PathLabs’ extensive healthcare network, reflecting Cardio Diagnostics’ commitment to advancing precision medicine globally.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardio Diagnostics Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260107882108) on January 07, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cardio Diagnostics Launches PrecisionCHD Test in India</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCardio Diagnostics Launches PrecisionCHD Test in India\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-07 19:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CDIO\">Cardio Diagnostics</a> Launches PrecisionCHD Test in India\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CDIOW\">Cardio Diagnostics</a> Holdings Inc., a leader in precision cardiovascular medicine, has announced its first international expansion through a strategic partnership with Aimil Ltd. and Dr. Lal PathLabs Limited to launch the PrecisionCHD™ test in India. This collaboration introduces Cardio Diagnostics' advanced epigenetics and AI-driven technology for the detection and management of coronary heart disease to the Indian market. The move aims to improve early detection and personalized treatment of heart disease across Dr. Lal PathLabs’ extensive healthcare network, reflecting Cardio Diagnostics’ commitment to advancing precision medicine globally.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardio Diagnostics Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260107882108) on January 07, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDIO","symbol_name":"CARDIO DIAGNOSTICS HOLDINGS INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL9DbTVC:1","article_id":"2601087223","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601087223","pubTimestamp":1767785111,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cardio Diagnostics Holdings Inc., a leader in precision cardiovascular medicine, has announced its first international expansion through a strategic partnership with Aimil Ltd. and Dr. Lal PathLabs Limited to launch the PrecisionCHD test in India. This collaboration introduces Cardio Diagnostics' advanced epigenetics and AI-driven technology for the detection and management of coronary heart disease to the Indian market. The move aims to improve early detection and personalized treatment of heart disease across Dr. Lal PathLabs’ extensive healthcare network, reflecting Cardio Diagnostics’ commitment to advancing precision medicine globally.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardio Diagnostics Holdings Inc. published the or","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CDIO":"CARDIO DIAGNOSTICS HOLDINGS INC","BK4139":"生物科技"},"translate_title":"Cardio Diagnostics在印度推出PrecisionCHD测试","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDIO":0.9},"content_text":"Cardio Diagnostics Launches PrecisionCHD Test in India\n    \n\nCardio Diagnostics Holdings Inc., a leader in precision cardiovascular medicine, has announced its first international expansion through a strategic partnership with Aimil Ltd. and Dr. Lal PathLabs Limited to launch the PrecisionCHD™ test in India. This collaboration introduces Cardio Diagnostics' advanced epigenetics and AI-driven technology for the detection and management of coronary heart disease to the Indian market. The move aims to improve early detection and personalized treatment of heart disease across Dr. Lal PathLabs’ extensive healthcare network, reflecting Cardio Diagnostics’ commitment to advancing precision medicine globally.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardio Diagnostics Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260107882108) on January 07, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}